Industry Symposia

Novartis Breakfast Symposium

Date: Monday 28th August 

Time: 7.00am to 8.00am (breakfast served from 6:45am)

Title: In Acromegaly, CONTROL IS CRITICAL

Content: Uncontrolled biochemical levels in acromegaly may increase mortality. 45% of patients treated with first generation SSAs remain uncontrolled. Next generation treatment options are now available that help achieve biochemical control and tumour volume shrinkage.         

Topic 1: Uncontrolled biochemical control in Acromegaly and associated co-morbidities
Topic 2: Signifor LAR (Pasreotide) in patients with inadequately controlled Acromegaly

Speakers: Professor Mark McLean and Dr Carmela Caputo

Chair: TBC

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

This session is supported and organised byNovartis large  

 

Eisai Breakfast Symposium

Date: Monday 28th August

Time: 7.00am to 8.00am (breakfast served from 6:45am)

Title: Navigating the new landscape of managing radio-iodine refractory differentiated thyroid Cancer

Content: The 10-year survival rate among patients with differentiated thyroid cancer that is refractory to radioiodine (iodine- 131) therapy is 10% from the time of detection of metastasis. Although treatment options have historically been limited, efforts have first targeted vascular endothelial growth factor (VEGF) and its refractory(VEGFR), since this signalling network has been associated with the aggressiveness and metastasis of thyroid cancer. In Australia there hasn't been any treatment available in the PBS for these patients. Now that there is an option, it is very important that the Endocrinologists know about the new landscape of managing radio-iodine refractory differentiated thyroid Cancer. The symposia will explain the date from the treatment, what the correct patient is, when to initiate and how to manage adverse effects.

Speakers: Professor Bruce Robinson, Associate Professor Roderick Clifton-Bligh, Associate Professor Ben Solomon
Chair: Professor Bruce Robinson

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

 This session is supported and organised byEisailogo

 

Pfizer Breakfast Symposium

Date: Tuesday 29th August 

Time: 7.00am to 8.00am (breakfast served from 6:45am)

Title: Somavert®(pegvisomant) – the role of a growth hormone receptor antagonist (GHRA) in uncontrolled acromegaly

Content:
- A clinical need for pegvisomant: a case presentation
- Treatment of uncontrolled acromegaly with pegvisomant – indication, efficacy, safety, genetic considerations
- Questions from the audience

Topic 1: Clinical need for growth hormone receptor antagonist (GHRA) in Australia
Topic 2: Treatment of uncontrolled acromegaly with Somavert® (pegvisomant)

Speakers: Professor Ken Ho and Professor Marta Korbonits
Chair: Prof. Ken Ho

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

 This session is supported and organised byPfizer Endocrine Care1

 

 


Our Sponsors